Drug Trial Radar · NCT06450366
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
Jul 8, 2024
Primary completion
Feb 14, 2025
Study completion Mar 28, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess whether enlicitide is superior to ezetimibe or bempedoic acid or ezetimibe + bempedoic acid in reducing low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia, and to evaluate its safety and tolerability. The primary study hypotheses are enlicitide is superior to ezetimibe, bempedoic acid, and ezetimibe + bempedoic acid on mean percent change from baseline in LDL-C at week 8.
Conditions
- Hypercholesterolemia
Interventions
EnlicitideDrug
Oral tablet
EzetimibeDrug
Oral tablet
Bempedoic AcidDrug
Oral capsule
Placebo for EnlicitideOther
enlicitide-matching placebo oral tablet
Placebo for EzetimibeOther
ezetimibe-matching placebo oral tablet
Placebo for Bempedoic AcidOther
bempedoic acid-matching placebo oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56Time frame: Baseline and Day 56
Locations
35 sites in 8 countries. Site status is shown where the registry gives one.
Clinical Trials Research ( Site 1509)
Lincoln, California
Healthcare Research Network - Chicago ( Site 1507)
Flossmoor, Illinois
L-MARC Research Center ( Site 1501)
Louisville, Kentucky
Velocity Clinical Research Rockville ( Site 1503)
Rockville, Maryland
Velocity Clinical Research, Gulfport ( Site 1505)
Gulfport, Mississippi
Piedmont Research Partners ( Site 1506)
Fort Mill, South Carolina
Rainier Clinical Research Center ( Site 1502)
Renton, Washington
Instituto de Investigaciones Clínicas Mar del Plata ( Site 1002)
Mar del Plata, Buenos Aires, Argentina
CIPREC-CIPREC Sede Arenales ( Site 1000)
Buenos Aires, Buenos Aires F.D., Argentina
Fundacion Estudios Clinicos ( Site 1001)
Rosario, Santa Fe Province, Argentina
The Medical Arts Health Research Group ( Site 1606)
Vancouver, British Columbia, Canada
Cambridge Cardiac Care Centre ( Site 1603)
Cambridge, Ontario, Canada
North York Diagnostic and Cardiac Centre ( Site 1605)
North York, Ontario, Canada
Institut de Cardiologie de Montreal ( Site 1604)
Montreal, Quebec, Canada
Diex Recherche Trois-Rivieres ( Site 1602)
Trois-Rivières, Quebec, Canada
Hôpital Bichat - Claude-Bernard ( Site 0504)
Paris, France
Hôpital Arnaud de Villeneuve - CHU Montpellier ( Site 0505)
Montpellier, Herault, France
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes-CIC Endocrinology-Diabetology-Nutrition ( Sit
Nantes, Loire-Atlantique, France
Hospices Civils de Lyon - Hopital Louis Pradel ( Site 0501)
Bron, Rhone, France
Yitzhak Shamir Medical Center. ( Site 0702)
Beer Yaakov, Israel
Assuta Beersheba MC ( Site 0704)
Beersheba, Israel
Rambam Health Care Campus ( Site 0700)
Haifa, Israel
Meir Medical Center. ( Site 0703)
Kfar Saba, Israel
EAP Sardenya ( Site 0800)
Barcelona, Spain
Hospital Universitari Vall d'Hebron ( Site 0803)
Barcelona, Spain
Hospital Universitario Virgen de la Victoria-UGC Endocrinologia y nutricion ( Site 0801)
Málaga, Andalusia, Spain
Hospital de Figueres ( Site 0804)
Figueres, Gerona, Spain
Hospital San Rafael de Coruna ( Site 0805)
A Coruña, La Coruna, Spain
National Cheng Kung University Hospital-Internal Medicine ( Site 0403)
Tainan, Taiwan
National Taiwan University Hospital ( Site 0400)
Taipei, Taiwan
Taipei Veterans General Hospital-Department of Medicine ( Site 0402)
Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 0404)
Taoyuan, Taiwan
Barts Health NHS Trust-William Harvey Clinical Research Centre ( Site 0901)
London, England, United Kingdom
Royal Free Hospital ( Site 0900)
London, England, United Kingdom
National Institute for Health Research UCLH Clinical Research Facility ( Site 0908)
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.